Charles Riv Labs Intl Inc Stock Price, News & Analysis

On April 13, 2023, Wheeler Bio, a contract development and manufacturing organization (CDMO), announced the closure of a $31 million Series A financing round, co-led by Charles River Laboratories (NYSE: CRL) and Echo. The funds will be used to complete a state-of-the-art CGMP cell banking and drug substance manufacturing facility in Oklahoma City, with production expected to start in Q3 2023. Wheeler Bio's primary service, Portable CMC™, integrates development services to address client timelines and budgets, reducing risks associated with drug development. The company focuses on delivering small batch production for next-gen therapeutic proteins, positioning itself at the forefront of CMC drug development.

Charles River Laboratories International, Inc. (NYSE: CRL) will release its first-quarter 2023 financial results on May 11, before the market opens. A conference call to discuss the results is scheduled for 8:30 a.m. ET on the same day. Investors can listen to the live webcast through the Investor Relations section of the company's website, with a replay available afterward.

Charles River provides critical products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions worldwide. Their focus is on enhancing research and drug development processes to assist in the discovery and safe manufacture of new therapies.

Charles River Laboratories (NYSE: CRL) is showcasing its enhanced oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. The company will present 19 scientific posters and a spotlight presentation focusing on next-generation technologies in drug discovery and cell therapy development. Charles River has significantly contributed to cancer therapy advancements, being named co-inventors on 78 patents and supporting 16 clinical candidates, along with 11 FDA-approved therapies since 2018. Collaborative efforts with Cypre, Inc. and Kibur Medical are also highlighted, showcasing innovative approaches including the use of 3D hydrogel tumor models and implantable microdevices for enhanced drug-response tracking.

Charles River Laboratories (NYSE: CRL) will present at the Barclays Global Healthcare Conference on March 15 at 10:15 a.m. ET. The management will discuss the company's strategic focus and recent business developments. A live webcast of the presentation will be available on the Investor Relations website and will be archived for two weeks following the event. Charles River is dedicated to supporting pharmaceutical and biotechnology sectors by providing essential products and services that expedite research and drug development efforts. For more information, visit www.criver.com.

Charles River Laboratories International (NYSE: CRL) announces the launch of Apollo™, a secure cloud-based platform designed for drug developers. This platform streamlines access to study data, milestones, documents, and cost estimates, ultimately enhancing decision-making and client experience. Apollo is part of Charles River's digital strategy, fostering real-time data access and self-service tools for clients. Currently live for ongoing studies, Apollo aims to improve efficiency in preclinical studies.

Charles River Laboratories (NYSE: CRL) has launched its off-the-shelf pHelper offering designed to streamline adeno-associated virus (AAV)-based gene therapy programs from discovery to commercial manufacturing. Available in Research Grade, High Quality, and Good Manufacturing Practice grades, this product aims to secure supply chains and support regulatory filings with reliable manufacturing. Key benefits include immediate supply, consistent quality, and cost reduction. The launch will be highlighted at the Gene Therapy Spotlight event on March 13 in London, showcasing the role of plasmid DNA in gene therapy manufacturing.

Charles River Laboratories (CRL) reported a strong performance for Q4 2022, with revenues of $1.10 billion, up 21.5% year-over-year, and full-year revenues reaching $3.98 billion, reflecting a 12.3% increase. GAAP EPS for Q4 was $3.65, a 36.7% rise, attributed to gains from the Avian Vaccine sale. Non-GAAP EPS also rose to $2.98, an increase of 19.7%. Looking ahead, CRL anticipates revenue growth of 1.5% to 4.5% in 2023, hindered by non-human primate (NHP) supply chain issues. Despite challenges, management emphasized sustainability in long-term growth.

Charles River Laboratories (CRL) has signed a multi-program agreement with Pioneering Medicines, enabling access to its AI-driven drug solution, Logica. Designed to expedite drug discovery, Logica combines Valo Health’s Opal Computational Platform and Charles River’s preclinical expertise. The collaboration aims to generate optimized small molecules for unmet medical needs within a 2-year timeframe. This integrated platform is expected to enhance efficiency in drug development, reducing costs tied to success. Flagship Pioneering's initiative, Pioneering Medicines, seeks to leverage innovative platforms to develop transformative treatments.

Charles River Laboratories (NYSE: CRL) has partnered with Purespring Therapeutics to develop a gene therapy platform focused on kidney diseases, affecting about 840 million people globally. This collaboration utilizes Charles River's eXpDNA™ plasmid manufacturing capabilities, bolstering their CDMO services in cell and gene therapy. Purespring aims to innovate treatments targeting podocytes, leveraging a lower-dose, local delivery approach to enhance efficacy and safety. Supported by significant investments, this initiative seeks to accelerate the development of novel therapies, transforming kidney disease treatment and significantly improving patient outcomes.